Psoriasis - Pipeline Review, Q4 2010

Description: Psoriasis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Psoriasis Pipeline Review, Q4 2010”, provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis. “Psoriasis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Psoriasis.
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Psoriasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Psoriasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Psoriasis Overview
Therapeutics Development
An Overview of Pipeline Products for Psoriasis
Psoriasis Therapeutics under Development by Companies
Psoriasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Psoriasis Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Micromet, Inc.
Novo Nordisk A/S
Nycomed International Management GmbH
Novartis AG
Actelion Ltd
Astellas Pharma Inc.
Biocon Limited
Cephalon, Inc.
LEO Pharma A/S
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Santarus, Inc.
Genmab A/S
Celgene Corporation
Merck KGaA
InNexus Biotechnology Inc.
Can-Fite BioPharma Ltd.
Idera Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc.
Lupin Limited
NicOx SA
Compugen Ltd.
CytoGenix, Inc.
Bio3 Research S.r.l
Tolerx, Inc.
ProMetic Life Sciences Inc.
Genizon BioSciences, Inc.
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
Biotie Therapies Corp.
Sosei Group Corporation
DARA BioSciences, Inc.
Provectus Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Piramal Life Sciences Limited
Digna Biotech, S.L.
D-Pharm Ltd.
Affimed Therapeutics AG
Viron Therapeutics, AG
Jenrin Discovery, Inc.
Devgen NV
Probiodrug AG
Physica Pharma
BioMAS Ltd.
Neovacs SA
MIKA Pharma GmbH
Hutchison MediPharma Limited
Cosmix Molecular Biologicals GmbH
CREABILIS Therapeutics S.r.l.
IMTM GmbH
Anacor Pharmaceuticals, Inc.
Airmid Incorporated
Gene Signal International SA.
Syntrix Biosystems, Inc.
Ferrer Internacional S.A.
MediQuest Therapeutics, Inc.
Xention Limited
TcL Pharma SAS
Virobay Inc.
Inimex Pharmaceuticals, Inc.
Y’s Therapeutics Co., Ltd.
Welichem Biotech Inc.
CBio Limited
SWITCH Biotech LLC
Hy BioPharma Inc.
BioCis Pharma Ltd.
KAHR medical Ltd.
Synphora AB
Kemin Industries, Inc.
Immune Control, Inc.
Cellceutix Pharmaceuticals, Inc.
Avontec GmbH
Sinapis Pharma, Inc
Mycenax Biotech Inc.
Celtic Pharmaceutical Holdings L.P.
Immune Technologies and Medicine
Innovaderm Research Inc.
Mantecorp Industria Quimica e Farmaceutica Ltda
Universities/Institutes Involved in Psoriasis Therapeutics Development
Psoriasis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
CF101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clobetasol Propionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Infliximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisolone Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tasocitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TuNEX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Dec 01, 2010: RegeneRx Receives Australian Patent For TB4
Nov 16, 2010: Allozyne Announces Positive Proof Of Concept Data For AZ17 For Treatment Of Autoimmune Diseases
Oct 11, 2010: Abbott Reports Psoriasis Phase III Results Of ABT-874
Oct 07, 2010: Pfizer's Oral Tasocitinib Demonstrates Statistically Significant Response By 12 Weeks In Phase II Plaque Psoriasis Study
Sep 14, 2010: Biotie's Phase I Trial With BTT-1023 Demonstrates Safety Profile
Sep 13, 2010: Forward Pharma Initiates Phase II Efficacy and Safety Trial For FP187
Jun 07, 2010: Can-Fite BioPharma Announces Opening Of CF101 Dermatology IND With Phase II/III Psoriasis Protocol
Jun 01, 2010: VBL To Present Anti-Inflammatory Properties Of VBL-201 At Keystone Symposium
May 07, 2010: VBL Therapeutics Announces Positive Preclinical Data For VB-201 Against Psoriasis

Ordering:

Order Online - http://www.researchandmarkets.com/reports/1464186/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psoriasis - Pipeline Review, Q4 2010
Web Address: http://www.researchandmarkets.com/reports/1464186/
Office Code: SCD2I3CC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: __________________________________________
Organisation: _______________________________________
Address: __________________________________________
City: _____________________________________________
Postal / Zip Code: ___________________________
Country: _______________________________________
Phone Number: _____________________________
Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World